key: cord-0054318-0d7j79mi
authors: Farne, Hugo; Singanayagam, Aran
title: Reply
date: 2020-12-30
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2020.11.019
sha: c5e434df64c9cec09537508c3f6075e2b63e18d0
doc_id: 54318
cord_uid: 0d7j79mi

nan

To the Editor:

We thank Lipworth et al 1 for their correspondence regarding our article recently published in the Journal of Allergy and Clinical Immunology. 2 We agree that it is currently unclear whether inhaled corticosteroid (ICS) use in chronic obstructive pulmonary disease (COPD) imparts an overall protective or detrimental effect on susceptibility to coronavirus disease 2019 (COVID-19). Theoretically, any potentially beneficial effects of ICS related to COVID-19, such as angiotensin-converting enzyme 2 attenuation and/or suppression of inflammation, could be offset by detrimental effects. For example, we have previously reported that ICSs suppress type I interferon, leading to secondary bacterial infections and mucus hypersecretion during respiratory viral infections. 3 It should also be noted that, in animal models, angiotensin-converting enzyme 2 has a protective functional role against acute lung injury 4 and thus the suppressive effect of ICSs may have adverse consequences in the context of active infection.

Lipworth et al cite the increased risk of death in patients with COPD taking any ICS combination therapy versus those on dual bronchodilators without ICS identified in the OpenSAFELY cohort. 5 It is worth noting that the increased risk for patients with COPD prescribed ICS/long-acting beta-agonist did not reach significance (adjusted hazard ratio, 1.29; 95% CI, 0.96-1.74), suggesting that the increased risk ascribed to triple ICS/long-acting beta-agonist/long-acting muscarinic antagonist therapy (1.43; 95% CI, 1.12-1.83) may not be solely related to the ICS component but possibly due to increased disease severity. This is supported by a negative control analysis showing an increase in deaths not related to COVID-19 in patients with COPD prescribed ICS (1.23; 95% CI, 1.08-1.40). 5 

Inhaled corticosteroids and angiotensin-converting enzyme-2 in COPD

Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon

Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform